These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22208481)

  • 1. Test verification and validation for molecular diagnostic assays.
    Halling KC; Schrijver I; Persons DL
    Arch Pathol Lab Med; 2012 Jan; 136(1):11-3. PubMed ID: 22208481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verification of performance specifications for a US Food and Drug Administration-approved molecular microbiology test: Clostridium difficile cytotoxin B using the Becton, Dickinson and Company GeneOhm Cdiff assay.
    Schlaberg R; Mitchell MJ; Taggart EW; She RC;
    Arch Pathol Lab Med; 2012 Jan; 136(1):20-5. PubMed ID: 22208483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array.
    Lacbawan FL; Weck KE; Kant JA; Feldman GL; Schrijver I;
    Arch Pathol Lab Med; 2012 Jan; 136(1):14-9. PubMed ID: 22208482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of fluorescence in situ hybridization using an analyte-specific reagent for detection of abnormalities involving the mixed lineage leukemia gene.
    Saxe DF; Persons DL; Wolff DJ; Theil KS;
    Arch Pathol Lab Med; 2012 Jan; 136(1):47-52. PubMed ID: 22208487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.
    Jennings LJ; Smith FA; Halling KC; Persons DL; Kamel-Reid S;
    Arch Pathol Lab Med; 2012 Jan; 136(1):33-40. PubMed ID: 22208485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab).
    Hamilton RG
    J Allergy Clin Immunol; 2006 Apr; 117(4):759-66. PubMed ID: 16630931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commercial molecular diagnostics in the U.S.: The Human Genome Project to the clinical laboratory.
    Amos J; Patnaik M
    Hum Mutat; 2002 Apr; 19(4):324-33. PubMed ID: 11933187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of molecular-diagnostic techniques in the parasitological laboratory.
    Conraths FJ; Schares G
    Vet Parasitol; 2006 Mar; 136(2):91-8. PubMed ID: 16414191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and analytical validation of clinical DNA sequencing assays.
    Pont-Kingdon G; Gedge F; Wooderchak-Donahue W; Schrijver I; Weck KE; Kant JA; Oglesbee D; Bayrak-Toydemir P; Lyon E;
    Arch Pathol Lab Med; 2012 Jan; 136(1):41-6. PubMed ID: 22208486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and integration of molecular genetic tests into clinical practice: the US experience.
    Amos J; Grody W
    Expert Rev Mol Diagn; 2004 Jul; 4(4):465-77. PubMed ID: 15225094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
    Goodsaid F; Frueh FW
    Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic DHPLC Quality Assurance (DDQA): a collaborative approach to the generation of validated and standardized methods for DHPLC-based mutation screening in clinical genetics laboratories.
    Schollen E; Dequeker E; McQuaid S; Vankeirsbilck B; Michils G; Harvey J; van den Akker E; van Schooten R; Clark Z; Schrooten S; Matthijs G;
    Hum Mutat; 2005 Jun; 25(6):583-92. PubMed ID: 15880509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to the Food and Drug Administration (FDA) regulatory process.
    Hackett JL; Gutman SI
    J Proteome Res; 2005; 4(4):1110-3. PubMed ID: 16083260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part IV - postanalytic considerations.
    Barnett D; Louzao R; Gambell P; De J; Oldaker T; Hanson CA;
    Cytometry B Clin Cytom; 2013; 84(5):309-14. PubMed ID: 24022853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues.
    Davis BH; Dasgupta A; Kussick S; Han JY; Estrellado A;
    Cytometry B Clin Cytom; 2013; 84(5):286-90. PubMed ID: 24022851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part I - rationale and aims.
    Davis BH; Wood B; Oldaker T; Barnett D
    Cytometry B Clin Cytom; 2013; 84(5):282-5. PubMed ID: 24022850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology.
    Gibbs JN
    Expert Rev Mol Diagn; 2011 May; 11(4):367-81. PubMed ID: 21545255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular laboratory tests for the diagnosis of respiratory tract infection due to Staphylococcus aureus.
    Peterson LR
    Clin Infect Dis; 2011 May; 52 Suppl 4():S361-6. PubMed ID: 21460297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.